On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first…
The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep…
To mark World Blood Cancer Day on 28 May, we are highlighting the important work of our Polish member, the Carita Foundation and how they have collaborated with us to raise awareness of important issues with Polish policymakers. The Carita Foundation has today participated in a meeting of the Parliamentary Working Group on Oncology in the Polish Parliament. This meeting…
To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 30 June at 17:00 CET. At this webinar you can expect clear explanations of the key research updates and…
At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the…
Bosnia and Herzegovina marks myeloma awareness month We are delighted to share an update from our member organisation in Bosnia and Herzegovina, who marked Myeloma Action Month with a series of meaningful activities in March. On 26 March, they organised a professional meeting in Tuzla, bringing together over 50 participants including haematologists, healthcare professionals, patients…
At the MPE Annual General Meeting on Tuesday, 31 March, we were pleased to welcome four new member organisations into the MPE community and to confirm the results of our board elections. Together, they represent the continued growth and diversity of the myeloma and amyloidosis patient community across Europe. New members Hellenic Multiple Myeloma Patient…
The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is…
